Eli Lilly & Company (NYSE:LLY) is highlighted as one of the best low volatility stocks to buy by analysts. Guggenheim reaffirmed its Buy rating on LLY and raised its price target to $942 ahead of second-quarter earnings, expecting strong Mounjaro and Zepbound sales.

Guggenheim projects Mounjaro sales to reach $4.49 billion in the second quarter, contrary to consensus estimates. They also anticipate Zepbound to generate $3.10 billion in US sales, slightly above the $2.94 billion consensus. The firm factors in a projected $0.14 impact on earnings per share from IPR&D.

Investors closely monitor net price and prescription trends for tirzepatide, as well as upcoming clinical trial outcomes until 2025. Eli Lilly, founded in 1876, is a leading global pharmaceutical company known for developing, manufacturing, and distributing various drugs.

While LLY shows potential as an investment, some AI stocks may offer higher growth and lower risk. For an undervalued AI stock with potential benefits from Trump-era tariffs and onshoring trends, check out the free report on the best short-term AI stock.

Read more at Yahoo Finance: Eli Lilly (LLY) Gets Price Target Boost as Analysts See Strong Mounjaro, Zepbound Sales